deuruxolitinib
Small moleculeapprovedFast Track FDA
Approved
Jul 25, 2024
Clinical trial activity
21 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
13
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started May 31, 2016 (NCT02777008)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 3 Sponsor(trial)
- Jul 25, 2024
Sun Pharmaceuticals — Earliest FDA Approval
- Jul 25, 2024
Sun Pharmaceuticals — NDA Organization
Indications
Approved for
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Tyrosine-protein kinase JAK3INHIBITOR
Tyrosine-protein kinase JAK3 inhibitor
Geater inhibitory potency for JAK1, JAK2 and TYK2 relative to JAK3.
- Tyrosine-protein kinase TYK2INHIBITOR
Tyrosine-protein kinase TYK2 inhibitor
Approval history
- approvedFast trackJul 25, 2024
Chemistry & pharmacology
Loading structure…
SMILES
[2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H]- Mol. weight
- 314.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594382 ↗
- ChEMBLCHEMBL4594381 ↗
Also known as
- ctp-543
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05478772 | Phase 1 | Jul 11, 2022 | Concert Pharmaceuticals |
| NCT05467709 | Phase 1 | Jun 21, 2022 | Concert Pharmaceuticals |
| NCT05467696 | Phase 1 | Jun 14, 2022 | Concert Pharmaceuticals |
| NCT05468749 | Phase 1 | Jun 6, 2022 | Concert Pharmaceuticals |
| NCT05467722 | Phase 1 | Jun 1, 2022 | Concert Pharmaceuticals |
| NCT05192369 | Phase 1 | Jan 4, 2022 | Concert Pharmaceuticals |
| NCT05041803 | Phase 3 | Oct 19, 2021 | Concert Pharmaceuticals |
| NCT04797650 | Phase 3 | May 27, 2021 | Concert Pharmaceuticals |
| NCT04843540 | Phase 1 | May 19, 2021 | Concert Pharmaceuticals |
| NCT04743414 | Phase 1 | Mar 2, 2021 | Concert Pharmaceuticals |
| NCT04784533 | Phase 2 | Feb 26, 2021 | Concert Pharmaceuticals |
| NCT04518995 | Phase 3 | Nov 2, 2020 | Concert Pharmaceuticals |
| NCT04309643 | Phase 1 | Apr 30, 2020 | Celerion, Concert Pharmaceuticals |
| NCT04092712 | Phase 1 | Sep 5, 2019 | Celerion, Concert Pharmaceuticals |
| NCT03941548 | Phase 2 | May 16, 2019 | Concert Pharmaceuticals |
| NCT03898479 | Phase 2 | Apr 4, 2019 | Concert Pharmaceuticals |
| NCT03880136 | Phase 1 | Mar 25, 2019 | Concert Pharmaceuticals |
| NCT03811912 | Phase 2 | Mar 21, 2019 | Concert Pharmaceuticals |
| NCT03137381 | Phase 2 | May 1, 2017 | Concert Pharmaceuticals |
| NCT02960945 | Phase 1 | Nov 1, 2016 | Concert Pharmaceuticals |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Concert Pharmaceuticals | For profit | 21 | 21 | 3 | 2016 |
| Celerion | For profit | 2 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sun Pharmaceuticals | For profit | NDA | Jul 25, 2024 |